Dinaciclib, a cyclin-dependent kinase inhibitor, suppresses cholangiocarcinoma growth by targeting CDK2/5/9

Cholangiocarcinoma (CCA) is a highly invasive cancer, diagnosed at an advanced stage, and refractory to surgical intervention and chemotherapy. Cyclin-dependent kinases (CDKs) regulate cell cycle progression and transcriptional processes, and are considered potential therapeutic targets for cancer....

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Sci Rep
Glavni autori: Saqub, Hera, Proetsch-Gugerbauer, Hannah, Bezrookove, Vladimir, Nosrati, Mehdi, Vaquero, Edith M., de Semir, David, Ice, Ryan J., McAllister, Sean, Soroceanu, Liliana, Kashani-Sabet, Mohammed, Osorio, Robert, Dar, Altaf A.
Format: Artigo
Jezik:Inglês
Izdano: Nature Publishing Group UK 2020
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7595101/
https://ncbi.nlm.nih.gov/pubmed/33116269
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-020-75578-5
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items